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Abstract
Background: Peripheral neuropathy is one most common, limiting and invalidating neurological symptom in
subjects with hepatitis C virus and mixed cryoglobulinemia. Notably, the medical therapy proposed to eradicate
HCV, can frequently exacerbate the painful neuropathy. Therefore, neuropathy therapies are insufficient and
inadequate, and comprise immunosuppressive drugs, such as steroid or cyclosporine, intravenous immunoglobulin
or plasma exchange. These have shown variable success in case reports, with a presumably temporary effect, but
with major side effects.
Methods: We assessed the effects of oxcarbazepine treatment in 67 cases of cryoglobulinemia related neuropathy,
who did not respond to either steroid or Gabapentin, or Pregabalin. Oxcarbazepine was chosen based on the
promising preliminary results.
Results: Patients treated with Oxcarbazepine showed a rapid, discrete and persistent relief of polyneuropathic
signs, without consistent side effects, and with a limited interaction with concomitant drugs.
Conclusions: These data favor the use of oxcarbazepine as a useful tool in the management of neuropathic pain
associated with Hepatitis–C cryoglobulin neuropathy.
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Background
Cryoglobulins are cold-precipitating immunoglobulins [1],
which form aggregates and immune complexes, outstrip-
ping the reticuloendothelial-clearing activity, depositing in
the human tissues, activating the complement, and finally
leading to tissue damage, promoting systemic inflammation
(usually occurring at the level of skin or kidneys). Otherwise
healthy individuals could present cryoglobulins, making
difficult to estimate their real prevalence in medical sets,
finally considered rare. Nevertheless, the variable clinical
manifestations reported in literature, might leads to under-
estimation of cryoglobulinemia diffusion.
Cryoglobulins can be divided into three types, following
the Brouet classification [2], essential, or secondary to
autoimmune pathologies and chronic medical conditions
(primarily chronic infections) and related to lymphoprolif-
erative diseases [2]. The second and third types, also
defined as mixed cryoglobulins [2, 3], composed by
monoclonal Ig rheumatoid factor and polyclonal IgG and
IgM rheumatoid factor, are seen very frequently in HCV
infections [3–7].
Despite varying from country to country, the prevalence
of peripheral neuropathies in HCV-associated cryoglobuli-
nemia substantially varies in the Mediterranean [1, 3, 8]. Of
note, HCV-related proteins are present in damaged skin,
blood vessels, and kidneys and seem to play a direct role in
the pathogenesis of the damages seen in the peripheral
nerve [1, 9, 10].
Pathological findings suggest a direct damage of the
small vessels around nerve, the so-called vasa nervorum
[3, 11, 12], due to a vasculitis or to necrotizing arteritis.
Both these conditions cause an ischemic damage of nerve
[3, 10, 13, 14]. HCV is directly responsive for inducing the* Correspondence: silvia.gazzin@fegato.it2Italian Liver Foundation, Centro Studi Fegato, AREA Science Park, Bldg. Q, Ss
14, km 163.5, 34149 Trieste, Italy
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Moretti et al. BMC Gastroenterology  (2018) 18:19 
DOI 10.1186/s12876-018-0751-9
inflammation cascade of events in the vessels, since it has
been demonstrated HCV-RNA in epineurial cells [15–17].
Peripheral neuropathy is the most common reported
symptom in patients with HCV-associated mixed cryo-
globulinemia [18–20], where it may be the first clinical
manifestation, despite its prevalence is still unknown.
There is only a report [14] assessing the prevalence of
peripheral neuropathy in HCV; neuropathy was found in
33% of patients without other cryoglobulinemia-related
symptoms and clinically, most frequently, patients
present a symmetrical sensory or motor-sensory poly-
neuropathy, or less frequently as a mono-neuropathy, or
as a multiple mononeuropathy [3, 15].
At biopsy, axonal degeneration is shown, possibly trig-
gered by the deposit of cryoglobulins at the level of vasa
nervosum microcirculation and vasculitis-induced ische-
mia, as well, despite seldom reported, by an immuno-
logical mediated demyelination. Electrophysiological
studies and teased nerve fiber studies allowed neuropa-
thies to be classified as predominantly sensory axonopa-
thies [21, 22], even if there are some descriptions of
demyelinating peripheral neuropathies [3, 21–24].
There is no conventional treatment for HCV cryo-
globulin neuropathy. It is accepted nowadays that pro-
longed antiviral therapy led to a reduction of HCV-RNA
levels, associated with a reduction of cryoglobulinemia
[25]. The reduction of cryoglobulins under the detect-
able levels has been obtained by treating patients with
interferon-alpha (IFN alpha) plus ribavirin, obtaining an
amelioration of painful polyneuropathy. On the other
hand, the side effects of IFN alpha therapy are known,
with the exacerbation of the symptoms of mixed cryo-
globulinemia, with an exacerbation of the neuropathy,
whit severe myalgia, arthralgia [26, 27]. Moreover, there
are different cases of described side effects of IFN alpha,
such as demyelinating sensory neuropathy, neuropsychi-
atric symptoms, a possible bone marrow dyscrasia, a
transient or definite worsening of hepatitis [22, 28, 29].
For cryoglobulin-related neuropathy, other options have
been proposed, including alternative immunosuppressive
agents, such as steroid or cyclosporine [30], and plasma
exchange [31]. They showed variable success and the ef-
fect is presumably temporary. There are some works
which stressed the importance of steroids and cyclo-
phosphamide [12]. Considering that peripheral
cryoglobulin-related neuropathy in HCV patients give,
as the most frequent symptom, the neuropathic pain,
the principle target should be its earliest relief and with-
out (or with the most limited) side effects.
After the promising results of a previous work [11], we
present a series of many patient, with HCV cryoglobuli-
nemia related polineuropathy, who did not respond to
steroid and Gabapentin treatment, but have been suc-
cessfully managed with Oxcarbazepine.
Methods
Patients
Sixty-seven HCV-positive patients (details in Tables 1 and
2) followed by the Liver Center of the University of Trieste
from 1st January 2000-to 1st January 2015, have been stud-
ied in the Neurology Unit due to the detection of periph-
eral neuropathic signs. All the patients were treated with
IFN-αlpha and ribavirin therapy, three times a week; a pro-
gressive decrease of their viral load was observed in all of
them. Neurological signs of peripheral neuropathic signs
appeared for 11 patients 9.7 ± 2.1 months after the cessa-
tion of antiviral therapy even with a sustained viral re-
sponse, and increase in the cryoglobulins serum level.
Forty-four patients interrupted antiviral therapy (mean
period of treatment of 7.6 9.7 ± 2.1) due to neurological
symptoms such as anxiety and depression (18 patients),
suicidal thoughts (6 patients), major sleeping disturbances,
concentration difficulties and daily living executive compli-
cations (8 patients), apathy, chronic fatigue, loss of weight
(12 patients). Drop out are in line with some data pre-
sented in Literature, i.e. by Manns et al. [32, 33] All the 44
patients showed cryoglobulin neuropathic polyneuropathy
3.4 ± 1.2 months after stopping antiviral therapy. Twelve
patients were strained to interrupt the IFN and ribavirin
therapy (after mean time of therapy duration of 6.2 ±
3.9 months) due to the appearance of painful peripheral
Table 1 Epidemiological and biological features in 67 patients
with HCV and cryoglobulinemia
Patients (total 67) Features
Age (years) 50.4 ± 2.7
Sex ratio (M/F) 31/36
Apparent duration of disease (years) 4.1 ± 1.3
Albumin level (g/L) 39.7 ± 8.5
ALT (IU/L) 131.4 ± 16.7
Prothrombin time (%) 84.1 ± 12.2
Rheumatoid factors (n of pts. and %) 41/67 (61%)
Mean Cryoglobulinemia(g/L) 0.27 ± 0.8
Cryoglobulinemia type
CGS TYPE II (n of pts. and %) 42/67 (64%)
CGS TYPE III (n of pts. and %) 25/67 (36%)
ANTI HCV Antibodies (n of pts. and %) 67/67 (100%)
ANTI HBV Antibodies (n of pts. and %) 35/67 (52%)
Anti HBC 30 (86%)
HBsAg 5 (14.2)
Anti HBS 30 (86%)
HBeAG 0
AntiHBe 0
HCV RNA sequences in sera (n of pts. and %) 49/67 (73%)
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neuropathy, associated with an elevation of cryoglobuline-
mia, and therefore excluding the IFN-related neuropathy.
The new antiviral drugs (sofusbuvir, simeprevir, dacla-
tasvir, etc.) were not used, since at the time of the recruit-
ment they were not available. All of the 67 patients
reported progressive painful paresthesias, shock pain epi-
sodes, boot-glove dysesthesia sensations. All the patients
showed signs of cryoglobulinemia (mean 0.27 +/− 0.8 g/L;
range 0.05–1.6 g/L). Cryocrit levels were measured as the
percentage of packed cryoglobulins after cold centrifuga-
tion of the serum, and cryoglobulin composition was de-
termined by immunodiffusion on Ouchterlony plates
against specific antisera. Fifty-eight had polyneuropathy
and 9 had mononeuropathy multiplex. All subjects had an
electroneurographic confirmation of peripheral neur-
opathy, 57 presented the axonal profile and 10 showed the
axonal-demyelinating signs of damage (Table 3). Thirty-
six patients referred a relatively acute onset of pain and
numbness in feet and legs together with a rash on the dor-
sal surface of low limbs, in particular, starting from the
feet, extending midway up to the legs. Seventeen patients
presented with the acute onset of pain, described as “elec-
tric shocks” which is followed by numbness in legs. These
symptoms started approximately two years prior presenta-
tion of overt liver disease, and gradually worsened. Four-
teen patients (all women) presented a mainly sensory
neuropathy, asymmetrical, with dysesthesia symptoms and
were committed due to a presumptive restless leg syn-
drome, which was not confirmed by the neurologist. All
the patients denied any other symptom such as fever,
chills, arthralgias or skin alterations, apart from those de-
scribed above, or other general hepatic-referable symp-
toms; 24 patients admitted alcohol consumption before
the beginning of IFN-alpha and ribavirin therapy.
Reduced complement C4 activity has been found in 39
patients; positive search for antinuclear antibodies has been
found in 13 patients, anti-mitochondrial in 19 patients and
C-reactive protein has been found in 32 patients.
Pharmacological treatment
As shown in Fig. 1, after the electroneurographic confirm-
ation of the clinical diagnosis of cryoglobulinemia related
polineuropathy, patient started a cycle of steroids for
14 days, followed by Gabapentin if steroids failed to im-
prove the simptoms. If Gabapentin treatement was not suc-
cessful or accompained by side effects, it was substituted
with Pregabalin, witch was soon interrupted for severe side
effects. After one month of wash-out, all the 67 patients,
who still complained for the neurological sympotms began
Table 2 HCV status of the 67 patients
Patients (total 67) (number and %) Features
Anti HCV antibodies 67/67 (100%)
Chronic Hepatitis 67/67 (100%)
Cirrhosis 6/67 (8.9%)
Presumed disease duration (years) 6.1 ± 2.7
Fibrosis score 1.9 ± 0.7
HAI score [47] 6.5 ± 1.2
HCV genotype (number and %)
1 43 (64.1%)
2 1 (1.5%)
3 21 (31.3%)
4 2 (3%)
Table 3 Electrophysiological and clinical features of the
examined patients
Symptoms Patients
Neuropathy type
Polyneuropathy 58
Mononeuropathy 9
Electrophisiological features
Demyelination 10
Axonal 57
67 patients
HCV+ PNS
STEROID PULSE 
THERAPY
14 DAYS
3RD CHOICE 
TREATMENT
PREGABALIN
23 PATIENTS
1.3 0.8 MTHS
67 PATIENTS
HCV+ PNS
OXCARBAZEPINE
300 MG T.I.D
AND TAPERING
2ND CHOICE 
TREATMENT
GABAPENTIN
1.4 1.2 MTHS
14 DAYS
WASH OUT
NO POSITIVE EFFECTS
+ SIDE EFFECTS
NO POSITIVE EFFECTS
+ SIDE EFFECTS
NO POSITIVE EFFECTS
+ SIDE EFFECTS
Fig. 1 Patients flowchart
Moretti et al. BMC Gastroenterology  (2018) 18:19 Page 3 of 6
Oxcarbazepine. A neuriological assesemsnt was performed
every month for 12 months after the start of Oxcarbaze-
pine treatement.
Statistical analyses
Statistical analyses were performed using SAS® software
(version 16.0 SAS® Software Inc., Cary, NC, USA).
Within-group changes from baseline were tested using
the Wilcoxon Signed Ranks test. Between-group com-
parisons of changes from baseline were tested using the
Marginal Homogeneity Test. Spearman correlation test
has been employed for each significant variable. This
was done for each efficacy variable. Results are presented
as mean changes from baseline with standard deviations,
and p-values are provided where appropriate.
Results
As in Fig. 1, after the clinical diagnosis all patients were
treated with steroids (up to 100 mg/daily of prednisone);
10 patients partially responded, 40 experienced steroidal
side effects, which causes interruption, and 17 did not
show any benefit.
One month after the steroid washout, gabapentin. It
was prescribed (1887 ± 205 mg/day) followed by a mod-
erate improvement in the painful sensation (average vis-
ual analog scale from 8 to 9 to 6–7). After one month of
follow-up, due to daytime sleepiness, nausea, dizziness
and gait alteration the drug was stopped. The average
duration of the treatment was 1.4 ± 1.2 months.
In 23 strongly motivated patients, pregabalin (50 mg,
t.i.d) was prescribed; 14 patients showed cholestatic and
liver damage, 2 presented overt jaundice and 7 patients a
prolongation of the prothrombin time. All side effects
subsided after the medication was stopped. No amelior-
ation of pain symptoms was observed.
At the end of this period of treatment (average time of
5.6 months), all the 67 patients reported side effects and
persistence of pain. After two weeks of washout of any
other pain-relief drug(s), oxcarbazepine was given at a
dose of 300 mg/day for a week, increased to 600 mg/day
the following week, and then further increased to
900 mg/day. The dosage was increased to 1200 mg/day
in 11 patients for 10.2 ± 2.3 days, due to persistence of
pain, to be then readjusted to 900 mg/day. Each patients
was follow-up monthly for 12 months, and each check-
up, the Short form McGill Pain Assessment Question-
naire (SF-MPQ) [34] was administered. The average SF-
MPQ was 32.1 ± 5.7 at baseline (average scores 24–36),
and decreased to 21.3 ± 2.3 (average scores 17–25, p <
0.001) after one month. The average SF-MPQ at 6-
month was 12.5 ± 3.7 (average scores 9–14; p < 0.001
over baseline). At the 6th month of follow-up, the dose
of Oxcarbazepine was reduced to 600 mg/day; 33 pa-
tients were pain free and maintained the dose for two
additional months while 34 increased to 900 mg/day. All
the 67 patients, who have been prescribed Oxcarbaze-
pine, completed the 12 months follow-up: 46 patient
arte asymptomatic and do not take any anti-epileptic
drug. All patients referred sleepiness and drowsiness at
the beginning of the therapy that rapidly disappeared; no
other side effects were observed.
Discussion
Hepatitis C is a serious health concern, affecting millions
of people worldwide. The majority of the subject positive
for HCV antibody are asymptomatic. More recently, cen-
tral (CNS) and peripheral nervous system (PNS) have
been studied as focal collateral damage regions, tightly
involved in HCV.
The treatment of HCV-cryoglobulins -associated PNS is
actually based IFN plus ribavirin therapy, eventually asso-
ciated with steroids [4, 35–37]. Studies have showed that
patients with HCV-associated cryoglobulinemia and
extra-hepatic manifestations treated with IFN-alpha alone
were reported to be responders (resolution of symptoms,
disappearance of cryoprecipitates and HCV RNA), with
only one tapering off of IFN-alpha after 3 years of treat-
ment with sustained resolution of HCV and cryoglobuli-
nemia [34]. However, long-term studies were not
performed and the results of long term follow-up are not
available [38–40]. The few data available seems to indicate
favorable outcomes in cryoglobulinemia HCV subjects
treated with corticosteroids [10, 39, 40]. Since chronic
steroid administration also increases the level of HCV
RNA, this treatment should be limited. Therefore, intra-
venous immunoglobulin or plasmapheresis should be con-
sidered as a therapeutic option [24]. In addition, in
patients with severe cryoglobulinemia-associated vasculitis
as those with rapidly progressive renal failure or neuro-
logical involvement, the antiviral therapy should be de-
layed for 2–4 months while they are treated with
aggressive scheme with plasmapheresis, high doses of cor-
ticosteroids and either cyclophosphamide or rituximab
[41]. Rituximab therapy has been used predominantly in
HCV-related mixed cryoglobulinemia refractory to or un-
suitable for corticosteroids and antiviral (IFN-α) therapy
[41]. The role of interferon to exacerbate cryoglobuline-
mia related neuropathy is still under evaluation, although
recent data obtained in 24 patients showed that
interferon-free regimen with new drugs as sofosbuvir re-
sulted in an almost complete clinical response of the vas-
culitis but still undefined effect on pain relief [42].
Painful neuropathy is a dramatic and persistent condi-
tion, which affects many patients, and is an invalidating
condition. The several options available for pain control
are confusing and daunting. The best solution seems to be
an escalating regime matching the intensity and nature of
the sensory components of the pain state. Moreover, in
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chronic conditions, such as HCV- related hepatitis, where
many different clinical details should be considered, pain
relief therapies should not interfere with the underline dis-
ease and the concomitant antiviral treatment. Therefore,
pain-treatment should be efficacious, should not interfere
with their general and hepatic condition, should not create
side effects as, in particular, disequilibrium, gait imbalance,
drowsiness and reduced vigilance.
Oxcarbazepine is a safe drug, without significant side ef-
fects, and the rarely described hepato-toxicity seems to be
related to a hypersensitivity or to a immune –mediated re-
sponse to some metabolites of the drug, rapidly and totally
reversible [43]. Oxcarbazepine should be careful monitored
by specialists, with reported side effects, which can be dis-
tinguished in: more common, but rapidly and spontaneously
solving side effects (1:100): Blurred vision, disequilibirum,
mental depression, emotional incontinence, cough and sore
throat sensation. Less common (less than 1:1000): Agitation,
awkwardness, mental confusion, persistent disequilibrium
associated with orthostatic hypotension, fast or irregular
heartbeat, thirst, muscle cramps, headache, skin rash, weak-
ness. Usually they spontaneously disappeared, and they do
not need a suspension of therapy. Rare (less than 1: 3500):
Anxiety, burning feeling in the chest or stomach, hives or
itching, irritability, restlessness, muscle pain or weakness,
purple spots on the skin and rectal bleeding; these needs a
careful medical examination, and the consequent decision
to stop it.
Oxcarbazapine possess intrinsic pain-relief properties
[44], either considering acute or chronic pain [44, 45]
and neuropathic pain [46]. The efficacy of previous stud-
ies, its safety, the good tolerance and the limited side ef-
fects leads to this study, which confirmed the previously
reported data [10]. Results are stable, we have not re-
ported serious adverse side effects and pain relief is
stable. Our study demonstrated that treatment of HCV-
cryoglobulins related neuropathy with oxcarbazapine is
effective in the large majority of patients at a dosage
which is rather well tolerated and is not associated with
any relevant side effect. The particular condition of these
patients (particularly vulnerable to hepatotoxicity), the
conspicuous potential interactions with concomitant
drugs taken by the patients (antiviral, etc), the rapid
beneficial effect (demonstrated by the decrease of the
average SF-MPQ), and the absence of consistent side ef-
fects (demonstrated by a good pattern of labs values)
favour to the useof oxcarbazepine in the management of
neuropathic pain.
Conclusions
In this work, patients not responsive to steroids, gaba-
pentin at high dosage and to pregabalin, benefit from
oxcarbazepine. The limited side effects, associated to the
favourable and rapid response, the reduced interaction
with concomitant drugs support the use of oxcarbaze-
pine as an effective and safe treatment of the of HCV-
cryoglobulins related neuropathy.
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